ClinicalTrials.gg
RecruitingNCT06590454REVISEUpdated Feb 12, 2026

REVerse Intestinal Metaplasia in the Stomach (REVISE)

A Phase 2 interventional study of Pyrvinium and Placebo in Gastric Intestinal Metaplasia and Gastric Precancer, sponsored by Katherine Garman. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Katherine Garman · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment.

A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.

Read the detailed description

The proposed study is an early Phase II Clinical Trial designed to generate additional data regarding safety and efficacy for the use of Pyrvinium, an FDA-approved drug no longer in active use. The study design includes enrollment in an observational cohort for a research-focused screening upper endoscopy to document the extent and type of gastric intestinal metaplasia in patients previously diagnosed with this condition using a standardized mapping protocol (as described below). This initial screening research endoscopy is needed as current clinical care is variable (due to lack of guidelines for mapping and surveillance). The investigators anticipate enrolling 60 participants in the observational cohort for intensive gastric mapping, and then of these 60 participants, 32 eligible participants (after determining eligibility based on presence of high-risk features of the gastric intestinal metaplasia with confirmed extensive gastric intestinal metaplasia) will be included in the randomized control trial to receive either Pyrvinium (n=16) or placebo (n=16).

Treatment is planned as followed:

2 weeks of Pyrvinium vs placebo (within 3 months of initial research endoscopy).

Following the initial endoscopy, participants will receive placebo or Pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days. The drug (or placebo) will be verified and dispensed from the investigational drug pharmacy using an IND with attention to safety and blinding to research participants and clinical research staff. The drug and placebo will be administered as liquid suspensions. Medication diary logs will be used and participants will be asked to return bottles that contained the medication.

All participants will be advised to use sunblock and wear protective clothing due to potential for sun-sensitivity.

02

Conditions studied

  • Gastric Intestinal Metaplasia
  • Gastric Precancer

Browse trials for

Keywords

  • Gastric Intestinal Metaplasia
  • Pyrvinium
03

In context

Metaplasia

45 studies on the registry are indexed under Metaplasia; 11 are open to participants now.

This study's planned enrollment of 32 is below the median of 100 across 26 interventional studies indexed under Metaplasia.

Browse Metaplasia studies →

Lead sponsor

This is the only study on the registry with Katherine Garman as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (including men, women, and non-binary individuals) over age 18 with known GIM with at least one high-risk feature (extensive vs limited, incomplete or mixed-type GIM, family history of stomach cancer),
  • Ability to provide ,
  • Evidence of prior but not active H. pylori infection

Exclusion criteria

Exclusion Criteria:

  • Active gastric cancer diagnosis,
  • High-risk of bleeding complications due to anticoagulants or underlying medical condition,
  • Pregnancy (which is a to non-emergent endoscopy due to anesthesia risks)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Active comparator
    Pyrvinium

    Participants will receive Pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.

    Drug: Pyrvinium

  • Placebo comparator
    Placebo

    Participants will receive placebo by mouth once each day for a total of 14 days.

    Drug: Placebo

Interventions

  • Pyrvinium (2 mg/kg) per day for 14 days

  • DrugPlacebo

    Placebo for 14 days

06

What researchers measure

Primary outcomes

  1. Change in the number of clinical biopsies with evidence of gastric intestinal metaplasia

    For the efficacy analysis, the investigators will primarily evaluate the change in the number of clinical biopsies with evidence of gastric intestinal metaplasia from the screening endoscopy to the follow-up endoscopy.

    Time frame: Screening endoscopy (baseline) to the follow-up endoscopy (4-8 weeks)

Secondary outcomes

  1. Number of clinical biopsies with evidence of gastric intestinal metaplasia

    Time frame: 1 year

  2. Number of clinical biopsies with complete gastric intestinal metaplasia

    Time frame: 1 year

  3. Number of clinical biopsies with incomplete gastric intestinal metaplasia

    Time frame: 1 year

  4. Number of clinical biopsies with presence of parietal cells (reversal of atrophy)

    Time frame: 1 year

  5. Number of clinical biopsies with presence of inflammation

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Dec 15, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06590454
Lead sponsor
Katherine Garman
Responsible party
Katherine Garman (Professor of Medicine, Duke University) — Sponsor-investigator
First posted
Sep 19, 2024
Start date
Dec 15, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Feb 12, 2026

Study contacts

Nicole Pavlus
Contact
nicole.pavlus@duke.edu
919-684-0311
Laura Hayes, MS
Contact
laura.hayes@duke.edu
919-684-8771
Katherine Garman, MD
principal investigator · Duke Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pyrvinium

Start the discussion